Literature DB >> 26698247

Effects of tumor-specific antigen induced by lentinan on murine H22 hepatocellular carcinoma immunoprophylaxis.

Y Wang1, X Han, Y-D Li, S-Y Zhao, D-J Zhang, Z-H Zhao, Y-B Wang.   

Abstract

OBJECTIVE: Hepatocellular carcinoma (HCC) is one of the most prevalent tumor types and the third most common form of morbidity in cancer-related deaths worldwide. Lentinan isolated from Lentinus edodes, is known to be a biologically active macromolecule with extremely strong activation of the human immune system such as host-mediated anti-cancer activity. The aim of this study is to investigate the immunoprophylaxis effect of the antigens induced by lentinan on murine hepatocellular carcinoma.
MATERIALS AND METHODS: The antigens were prepared by a co-culture method (HCL) and purified by ammonium sulfate fractionation precipitation (Z1, Z2, Z3). The effects of antigens on murine hepatocellular carcinoma immunoprophylaxis were determined in vivo. The cellular immunity of the immunized mice was tested by spleen lymphocyte proliferation tests and peritoneal macrophage phagocytosis assays. The tumor-specific antigen was confirmed by Western blot analysis.
RESULTS: Results in vivo revealed that the antigens (HCL/Z1) activated immunoprophylaxis against hepatocellular carcinoma with a better survival status. The survival rates (60%, 100%) of the HCL/Z1 group were better than the model group (p < 0.01). The quantity of lymphocytes in the spleen in the HCL or Z1 groups treated with ConA or LPS were higher than that of the model group (p < 0.01). The phagocytosis ability of macrophages in the HCL or Z1 groups was better than that of the control group or model group (p < 0.01). The characterization of Western blot analysis showed that about 59.6 kDa tumor specific antigen combined with antiserum of immunized mice specifically appeared in antigens.
CONCLUSIONS: The newly generated tumor-specific antigen played a key role in the anti-tumor immune response and in activating the immune system. Our results suggest that this protein could serve as a tumor vaccine, and it could generate new ideas for tumor immunoprophylaxis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26698247

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

Review 1.  Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China.

Authors:  Yiran Zhang; Meng Zhang; Yifei Jiang; Xiulian Li; Yanli He; Pengjiao Zeng; Zhihua Guo; Yajing Chang; Heng Luo; Yong Liu; Cui Hao; Hua Wang; Guoqing Zhang; Lijuan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-24       Impact factor: 4.553

2.  Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice.

Authors:  Xuhua Duan; Manzhou Wang; Xinwei Han; Jianzhuang Ren; Guohao Huang; Shuguang Ju; Qinghui Zhang
Journal:  Cell Cycle       Date:  2020-12-07       Impact factor: 4.534

3.  Effects of intratumoral injection of immunoactivator after microwave ablation on antitumor immunity in a mouse model of hepatocellular carcinoma.

Authors:  Hao Wu; Bin Chen; Baogang Peng
Journal:  Exp Ther Med       Date:  2017-12-14       Impact factor: 2.447

4.  Lentinan Attenuates Damage of the Small Intestinal Mucosa, Liver, and Lung in Mice with Gut-Origin Sepsis.

Authors:  Zhongshen Kuang; Tingting Jin; ChangYi Wu; Yanan Zong; Panpan Yin; WangYu Dong; Xue Lin; WeiYan You; Chenlong Zhang; Lijie Wang; Yongying Liu; Shan Ren; Jiangwen Yin; Hang Xu
Journal:  J Immunol Res       Date:  2021-11-08       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.